Search results for "MVA"

showing 9 items of 89 documents

Simvastatin in vitiligo: an update with recent review of the literature.

2021

Patients with vitiligo often seek medical attention, as it diminishes their quality of life resulting in significant morbidity. Several topical and systemic therapies are in vogue targeting the immunological aspect of this disease, but results are often unsatisfactory, and complete cure remains elusive. Recently, simvastatin, a 3-hydroxy-3-methylyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, is being evaluated for vitiligo management because of its multimodal action, easy availability, and low cost. The proposed multimodal actions range from anti-inflammatory, antioxidant, to immunomodulatory properties which may be of therapeutic benefit in vitiligo patients. The authors intend to eva…

medicine.medical_specialtySimvastatinintegumentary systembusiness.industryVitiligoDermatologyDiseaseVitiligomedicine.disease030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeSimvastatin030220 oncology & carcinogenesismedicineQuality of LifeHumansHydroxymethylglutaryl-CoA Reductase Inhibitorsskin and connective tissue diseasesIntensive care medicinebusinessMedical attentionmedicine.drugInternational journal of dermatologyReference
researchProduct

The addition of simvastatin administration to cold storage solution of explanted whole liver grafts for facing ischemia/reperfusion injury in an area…

2018

Abstract Background Liver transplantation is the best treatment for end-stage liver disease. The interruption of the blood supply to the donor liver during cold storage damages the liver, affecting how well the liver will function after transplant. The drug Simvastatin may help to protect donor livers against this damage and improve outcomes for transplant recipients. The aim of this study is to evaluate the benefits of treating the donor liver with Simvastatin compared with the standard transplant procedure. Patient and methods We propose a prospective, double-blinded, randomized phase 2 study of 2 parallel groups of eligible adult patients. We will compare 3-month, 6-month, and 12-month g…

medicine.medical_specialtySimvastatinmedicine.medical_treatmentlcsh:SurgeryCold storageIschemia/reperfusion injury030230 surgeryLiver transplantationDonor after brain deathPlaceboProtective Agents03 medical and health sciencesLiver diseaseStudy Protocol0302 clinical medicineDouble-Blind MethodDonor after brain death; Ischemia/reperfusion injury; Liver transplantation; SimvastatinMedicineHumansProspective StudiesLiver transplantationbusiness.industrylcsh:RD1-811General Medicinemedicine.diseaseSurgeryTransplantationFatty LiverRegimenLiverSimvastatinReperfusion Injury030211 gastroenterology & hepatologySurgerybusinessReperfusion injurymedicine.drugBMC surgery
researchProduct

Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?

2015

Simvastatin and fenofibrate are the most frequently co-prescribed drugs for the treatment of dyslipidemia, manifesting beneficial effects on non-lipid parameters as well. The combination of these two drugs has been shown to increase success in the management of combined hyperlipidemia. Their different mechanism of action allows for the targeting of two types of lipid abnormalities: increased cholesterol and atherogenic dyslipidemia. Clinical studies have demonstrated that statin and fibrate combination therapy is effective in improving multiple lipid abnormalities, that may further decrease overall cardiovascular (CV) risk of patients with combined dyslipidemia. However, the clinical use of…

medicine.medical_specialtyStatinFenofibrateCombination therapymedicine.drug_classbusiness.industrynutritional and metabolic diseasesFibratemedicine.diseaseClinical trialCombined hyperlipidemiaSimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)businessDyslipidemiamedicine.drug
researchProduct

Rational for statin use in psoriatic patients

2013

Psoriasis represents a common skin disease which is clinically manifested by chronic cutaneous lesions. It has been observed that psoriasis is associated with an increased risk of cardiovascular diseases, which is contributed to the inappropriate lipid metabolism. Statins are commonly used in clinical practice to lower cholesterol concentration and, accordingly, decrease the individual risk of developing a cardiovascular episode. There have been reports that statin administration could also result in better management of psoriasis. The observed beneficial effects are contributed to the effects on lipid metabolism, including that in skin, as well as anti-inflammatory and immunomodulatory pro…

medicine.medical_specialtyStatinmedicine.drug_classAtorvastatinDermatologyDiseasePharmacologychemistry.chemical_compoundPsoriasisInternal medicinemedicineAnimalsHumansPsoriasiscardiovascular diseasesSkinCholesterolbusiness.industrynutritional and metabolic diseasesPsoriasis Statins Cholesterol Atorvastatin Fluvastatin SimvastatinGeneral Medicinemedicine.diseaseTreatment OutcomechemistrySimvastatinlipids (amino acids peptides and proteins)Dermatologic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatin
researchProduct

Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia

1995

SummaryThromboxane (Tx) A2 biosynthesis is enhanced in the majority of patients with type IIa hypercholesterolemia. Because blood clotting activation is an important component of the inflammatory response, involved in the initiation and progression of atherosclerotic plaques, we have investigated TxA2 biosynthesis, neutrophil activation and thrombin generation in 24 patients with type IIa hypercholesterolemia.Urinary 11-dehydro-TxB2, was significantly higher (p =0.0001) in patients than in 24 sex- and age matched healthy subjects. Similarly, prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complexes and plasma elastase were significantly higher in patients than incontrols. Urinary…

medicine.medical_specialtyThromboxaneChemistryElastaseHematologyGranulocyteThrombinEndocrinologymedicine.anatomical_structureSimvastatinInternal medicinemedicinelipids (amino acids peptides and proteins)PlateletLovastatinPancreatic elastasecirculatory and respiratory physiologymedicine.drug
researchProduct

Helsekommunikasjon som skreddersøm : en analyse av samvalgsverktøy og av helsepersonells holdninger til bruk av samvalgsverktøy

2016

Masteroppgave samfunnskommunikasjon- Universitetet i Agder, 2016 Pasientinvolvering er et hett tema i dagens helse-Norge. Pasientene er mer aktive, krever mer informasjon og mer bestemmelsesrett enn tidligere. Denne oppgaven retter fokus mot hvordan helsepersonell opplever denne endringen. I studien undersøkes det hvordan metoden samvalg med bruk av digitalt samvalgsverktøy påvirker helsepersonells måte å kommunisere med pasienter på. Både hvilke muligheter og utfordringer det digitale beslutningsverktøyet gir for kommunikasjonen med pasienter, og hvilke holdninger helsepersonell har knyttet til dette vil undersøkes. For å belyse problemstillingen gis det et teoretisk rammeverk knyttet til …

pasientinvolveringhelsepersonellkommunikasjonpasienterKOM500beslutningsverktøysamvalgsverktøyVDP::Social science: 200::Media science and journalism: 310
researchProduct

Kāda biomasas gazifikācijas modeļa skaitliskā analīze

2017

Šajā darbā tiek pētīts gazifikācijas procesa matemātiskais modelis. Tiek analizēta siltumapmaiņas reakcijas vienādojumu sistēma, konstruēts tās matemātiskais modelis un izpētīti raksti par gazifikācijas norises procesiem.

siltumvadīšanas vienādojumsmatemātiskais modelisdiferenču shēma.Matemātikafinite difference methodsgazifikācija
researchProduct

Effetti “beyond-cholesterol” delle statine: la terapia con simvastatina riduce le lipoproteine aterogene in pazienti con coronaropatia prematura

2002

statine simvastatina le lipoproteine aterogene coronaropatia
researchProduct

Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease

2002

statins simvastatin atherogenic lipoproteins coronary artery disease
researchProduct